Trial Profile
A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Crossover Study to Investigate the Abuse Potential of Purified Cannabidiol in Subjects with a History of Recreational Polydrug Use
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2018
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary) ; Alprazolam; Dronabinol
- Indications Cerebral ischaemia; Dravet syndrome; Duchenne muscular dystrophy; Epilepsy; Infantile spasms; Lennox-Gastaut syndrome; Opioid-related disorders; Ovarian cancer; Parkinson's disease; Schizophrenia; Tuberous sclerosis
- Focus Pharmacodynamics
- Sponsors GW Research
- 11 May 2018 New trial record
- 27 Apr 2018 Results presented at the 70th Annual Meeting of the American Academy of Neurology.